NCT06925737 2026-04-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
32 trialsNCT07005154 2026-04-02
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT06952803 2026-03-10
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT02125617 2026-01-14
uPARCRPC
Rigshospitalet, Denmark
Terminated
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT05295927 2025-02-03
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC
Phase 1 Terminated
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT01485861 2023-09-14
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Genentech, Inc.
Phase 1/2 Completed
NCT00268476 2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3 Active not recruiting
NCT04736108 2021-02-08
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
West China Hospital
Phase 2 Unknown
NCT01685983 2019-03-15
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01834209 2018-11-07
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
No longer available
NCT01756638 2017-10-23
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT01795703 2015-11-04
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
Janssen Research & Development, LLC
Phase 2 Completed
NCT01324583 2015-01-07
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sanofi
Phase 1 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed
NCT00638690 2014-04-30
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Cougar Biotechnology, Inc.
Phase 3 Completed
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed